118 related articles for article (PubMed ID: 34434504)
1. Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Hideshima T; Mazitschek R; Qi J; Mimura N; Tseng JC; Kung AL; Bradner JE; Anderson KC
Oncotarget; 2021 Aug; 12(17):1736. PubMed ID: 34434504
[TBL] [Abstract][Full Text] [Related]
2. HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Hideshima T; Mazitschek R; Qi J; Mimura N; Tseng JC; Kung AL; Bradner JE; Anderson KC
Oncotarget; 2017 Oct; 8(46):80109-80123. PubMed ID: 29113288
[TBL] [Abstract][Full Text] [Related]
3. HDAC6 inhibitor WT161 induces apoptosis in retinoblastoma cells and synergistically interacts with cisplatin.
Sun J; Qian X; Zhang F; Tang X; Ju C; Liu R; Zhou R; Zhang Z; Lv XB; Zhang C; Huang G
Transl Cancer Res; 2019 Dec; 8(8):2759-2768. PubMed ID: 35117033
[TBL] [Abstract][Full Text] [Related]
4. Correction: Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling.
Peake BF; Eze SM; Yang L; Castellino RC; Nahta R
Oncotarget; 2020 Nov; 11(44):4074-4075. PubMed ID: 33216843
[TBL] [Abstract][Full Text] [Related]
5. Correction: γKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancers.
Trošt N; Peña-Llopis S; Koirala S; Stojan J; Potts PR; Fon Tacer K; Martinez ED
Oncotarget; 2019 Jan; 10(8):916. PubMed ID: 30783519
[TBL] [Abstract][Full Text] [Related]
6. Correction: Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients.
Wang D; Lu P; Zhang H; Luo M; Zhang X; Wei X; Gao J; Zhao Z; Liu C
Oncotarget; 2021 May; 12(10):1024-1025. PubMed ID: 34012514
[TBL] [Abstract][Full Text] [Related]
7. Correction: MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer.
Lagendijk M; Saadatmand S; Koppert LB; Tilanus-Linthorst MMA; de Weerd V; Ramírez-Moreno R; Smid M; Sieuwerts AM; Martens JWM
Oncotarget; 2018 Aug; 9(62):32096. PubMed ID: 30174799
[TBL] [Abstract][Full Text] [Related]
8. Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells.
Zhao M; Zhuo ML; Zheng X; Su X; Meric-Bernstam F
Oncotarget; 2019 Dec; 10(65):7014-7015. PubMed ID: 31857856
[TBL] [Abstract][Full Text] [Related]
9. Correction: Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents.
Gaston J; Cheradame L; Yvonnet V; Deas O; Poupon MF; Judde JG; Cairo S; Goffin V
Oncotarget; 2019 Jun; 10(41):4249-4251. PubMed ID: 31289622
[TBL] [Abstract][Full Text] [Related]
10. Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience.
Yuan Y; Yost SE; Yim J; Yuan YC; Solomon NM; Mambetsariev I; Pal S; Frankel P; Salgia R; Neuhausen SL; Mortimer J
Oncotarget; 2017 Sep; 8(37):62817. PubMed ID: 28977992
[TBL] [Abstract][Full Text] [Related]
11. Correction: Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.
Ahmed MA; Selzer E; Dörr W; Jomrich G; Harpain F; Silberhumer GR; Müllauer L; Holzmann K; Grasl-Kraupp B; Grusch M; Berger W; Marian B
Oncotarget; 2019 Sep; 10(51):5385-5386. PubMed ID: 31555396
[TBL] [Abstract][Full Text] [Related]
12. Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
Robb CM; Kour S; Contreras JI; Agarwal E; Barger CJ; Rana S; Sonawane Y; Neilsen BK; Taylor M; Kizhake S; Thakare RN; Chowdhury S; Wang J; Black JD; Hollingsworth MA; Brattain MG; Natarajan A
Oncotarget; 2020 Jun; 11(25):2462-2463. PubMed ID: 32637035
[TBL] [Abstract][Full Text] [Related]
13. Correction: Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget.
Qiu YQ; Yang CW; Lee YZ; Yang RB; Lee CH; Hsu HY; Chang CC; Lee SJ
Oncotarget; 2019 Aug; 10(47):4919. PubMed ID: 31448057
[TBL] [Abstract][Full Text] [Related]
14. Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.
Borst GR; Kumareswaran R; Yücel H; Telli S; Do T; McKee T; Zafarana G; Jonkers J; Verheij M; O'Connor MJ; Rottenberg S; Bristow RG
Oncotarget; 2020 Apr; 11(17):1573-1574. PubMed ID: 32391125
[TBL] [Abstract][Full Text] [Related]
15. Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin.
Liang S; Peng X; Li X; Yang P; Xie L; Li Y; Du C; Zhang G
Oncotarget; 2022; 13():583-584. PubMed ID: 35391718
[TBL] [Abstract][Full Text] [Related]
16. Correction: Checkpoint inhibitor induced cardiotoxicity: managing the drawbacks of our newest agents against cancer.
Brüstle K; Heidecker B
Oncotarget; 2018 Sep; 9(70):33440. PubMed ID: 30279972
[TBL] [Abstract][Full Text] [Related]
17. Correction: Hypericin targets osteoclast and prevents breast cancer-induced bone metastasis via NFATc1 signaling pathway.
Ouyang Z; Guo X; Chen X; Liu B; Zhang Q; Yin Z; Zhai Z; Qu X; Liu X; Peng D; Shen Y; Liu T; Zhang Q
Oncotarget; 2019 Oct; 10(58):6283-6284. PubMed ID: 31692899
[TBL] [Abstract][Full Text] [Related]
18. Correction: By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy.
Petrelli A; Carollo R; Cargnelutti M; Iovino F; Callari M; Cimino D; Todaro M; Mangiapane LR; Giammona A; Cordova A; Montemurro F; Taverna D; Daidone MG; Stassi G; Giordano S
Oncotarget; 2019 Aug; 10(48):5003-5004. PubMed ID: 31452840
[TBL] [Abstract][Full Text] [Related]
19. Correction: Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer.
Lee KM; Lee M; Lee J; Kim SW; Moon HG; Noh DY; Han W
Oncotarget; 2021 Jun; 12(12):1197-1198. PubMed ID: 34136088
[TBL] [Abstract][Full Text] [Related]
20. Correction: PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix.
Mann M; Kumar S; Chauhan SS; Bhatla N; Kumar S; Bakhshi S; Gupta R; Sharma A; Kumar L
Oncotarget; 2019 Jul; 10(46):4802. PubMed ID: 31413820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
